Neuroendocrine Carcinoma Clinical Trial
Official title:
A Randomized, Controlled Phase II Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with
cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or
metastatic gastrointestinal pancreatic and esophageal neuroendocrine carcinoma.
In this prospective randomized phase II study, the investigators aim to compare the survival
benefit as well as the safety for irinotecan combined with cisplatin (IP regimen) versus
etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal
pancreatic and esophageal neuroendocrine carcinoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01642251 -
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04069299 -
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
|
||
| Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
| Recruiting |
NCT04325425 -
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
|
Phase 2 | |
| Completed |
NCT03834701 -
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
|
N/A | |
| Recruiting |
NCT03279614 -
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05978284 -
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076786 -
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
| Completed |
NCT00388063 -
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT03901378 -
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02970786 -
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans
|
Phase 1 | |
| Completed |
NCT00663429 -
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
| Completed |
NCT03278405 -
Avelumab in G3 NEC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03837977 -
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06372626 -
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
| Active, not recruiting |
NCT02687958 -
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
|
Phase 2 | |
| Completed |
NCT01121939 -
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
|
Phase 2 | |
| Recruiting |
NCT03168607 -
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 |